Insmed Incorporated (LON:0JAV)

Market Cap	28.00B
Revenue (ttm)	332.56M
Net Income (ttm)	-880.70M
Shares Out	n/a
EPS (ttm)	-4.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,441
Average Volume	1,335
Open	180.00
Previous Close	169.01
Day's Range	170.08 - 190.50
52-Week Range	61.28 - 214.00
Beta	1.09
RSI	40.94
Earnings Date	Feb 27, 2026

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 1,271
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0JAV

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD